Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 7/20 | 0.68 |
| ▸ | NPC1 | O15118 | 6/20 | 0.68 |
| ▸ | POLB | P06746 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.65 |
| ▸ | RELA | Q04206 | 2/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 4/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21643946 | 0.90 | GAA (0.72) | ALDH1A1SMN1; SMN2HTTRAB9ANPC1 | |
| SCHEMBL179086 | 0.87 | SMN1; SMN2 (0.77) | ALDH1A1SMN1; SMN2HTTRAB9ANPC1 | |
| SCHEMBL29975649 | 0.85 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2HTTRAB9ANPC1 | |
| SCHEMBL28366072 | 0.85 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2HTTRAB9ANPC1 | |
| SCHEMBL5385481 | 0.84 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2HTTRAB9ANPC1 | |
| SCHEMBL4008895 | 0.84 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2HTTRAB9ANPC1 | |
| SCHEMBL12182474 | 0.84 | GAA (0.82) | ALDH1A1SMN1; SMN2HTTRAB9ANPC1 | |
| SCHEMBL5385475 | 0.84 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2HTTRAB9ANPC1 | |
| SCHEMBL23080078 | 0.83 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2HTTRAB9ANPC1 | |
| SCHEMBL179015 | 0.81 | RAB9A (0.71) | ALDH1A1SMN1; SMN2HTTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420977-B2 | Late SV40 (LSF) inhibitors | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-08-23 | — | — | US | disclosed |
| WO-2022051388-A2 | QUINOLIN-2(1H)-ONE INHIBITORS OF LATE SV40 FACTOR | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20220062272-A1 | QUINOLIN-2(1H)-ONE INHIBITORS OF LATE SV40 FACTOR | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-03 | — | — | US | disclosed |
| EP-3829583-A1 | LATE SV40 FACTOR (LSF) INHIBITORS | Trustees of Boston University (US) | 2021-06-09 | — | — | EP | disclosed |
| CN-112770752-A | Late SV40 factor (LSF) inhibitors | 波士顿大学董事会 | 2021-05-07 | — | — | CN | disclosed |
| WO-2020028757-A1 | LATE SV40 FACTOR (LSF) INHIBITORS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020028757-A1 | LATE SV40 FACTOR (LSF) INHIBITORS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-02-06 | — | — | WO | disclosed |
| US-20200039996-A1 | LATE SV40 (LSF) INHIBITORS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-02-06 | — | — | US | disclosed |
| US-10392398-B2 | Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180051033-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2018-02-22 | — | — | US | disclosed |
| US-9815845-B2 | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-11-14 | — | — | US | disclosed |
| US-9802948-B2 | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERISTY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170107227-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170044175-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-02-16 | — | — | US | disclosed |
| EP-0927177-B1 | NOVEL BENZOTHIOPHENE DERIVATIVES, THEIR PREPARATION AND USE AS UROKINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-6274619-B1 | FUSED AMIDINO TYPE COMPOUNDS SUCH AS 4-(N-BUTYLCARBAMOYLMETHYLIDENE)-2-AMIDINO-4,5,6,7-TETRAHYDROBE NZO(B)THIOPHENE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-14 | — | — | US | disclosed |
| US-6093710-A | AN ENZYME INHIBITOR TREATING ANGIOGENESIS, ARTHRITIS, INFLAMMATION, METASTASIS, OSTEOPOROSIS, TUMORSANGIOGENESIS-DEPENDENT RETINOPATHIES, CONTRACEPTIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
| EP-0927177-A1 | NOVEL BENZOTHIOPHENE DERIVATIVES, THEIR PREPARATION AND USE AS UROKINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998011089-A1 | NOVEL BENZOTHIOPHENE DERIVATIVES, THEIR PREPARATION AND USE AS UROKINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062272-A1 | QUINOLIN-2(1H)-ONE INHIBITORS OF LATE SV40 FACTOR | NUTF2, UBTF, TUBB1 | ALDH1A1 2414/4885SMN1; SMN2 4593/4885HTT 1510/4885 |
| US-20170107227-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | GTF2F1, HDGF, GTF3C5 | ALDH1A1 3189/4885SMN1; SMN2 4673/4885HTT 2475/4885 |
| US-20200039996-A1 | LATE SV40 (LSF) INHIBITORS | DNMT1, ASF1A, DOT1L | ALDH1A1 3442/4885SMN1; SMN2 3759/4885HTT 2535/4885 |
| US-11420977-B2 | Late SV40 (LSF) inhibitors | ASF1A, DOT1L, DNMT1 | ALDH1A1 3733/4885SMN1; SMN2 4093/4885HTT 1850/4885 |
| US-20170044175-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | GTF2F1, HDGF, GTF3C5 | ALDH1A1 3189/4885SMN1; SMN2 4673/4885HTT 2475/4885 |
| US-20180051033-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | GTF2F1, HDGF, GTF3C5 | ALDH1A1 3189/4885SMN1; SMN2 4673/4885HTT 2475/4885 |
| US-10392398-B2 | Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics | GTF2F1, HDGF, GTF3C5 | ALDH1A1 3189/4885SMN1; SMN2 4673/4885HTT 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.